Stockscreener 앱 받기
6.925
3.28%
-0.235
전일 마감가:
$7.16
열려 있는:
$7.14
하루 거래량:
1.21M
Relative Volume:
0.80
시가총액:
$457.14M
수익:
$170.44M
순이익/손실:
$-193.88M
주가수익비율:
-1.8446
EPS:
-3.7541
순현금흐름:
$-126.38M
1주 성능:
-14.19%
1개월 성능:
-13.22%
6개월 성능:
-24.65%
1년 성능:
-43.88%
1일 변동 폭
$6.875
$7.18
1주일 범위
$6.80
$8.29
52주 변동 폭
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
6.925 | 457.14M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-05 | 개시 | Mizuho | Outperform |
| 2026-08-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX). - Stock Titan
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - www.marketscreener.com
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - PR Newswire
Gene Therapy Patent Suit Against Sarepta Comes To Close - Law360
Regenxbio, Penn End Revived Sarepta Gene-Therapy Patent Fight - Bloomberg Law News
Exclusive BAC Article: REGENXBIO; BLA Submisison RGX-202 DMD Q3 2026, Topline Data Ph3 ABBV-RGX-314 Wet-AMD Q4 2026, And Catalysts (NASDAQ:RGNX) - Seeking Alpha
Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin - GuruFocus
RGNX Initiates Coverage On Mizuho -- Rating Set to Outperform - GuruFocus
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call - Yahoo Finance
Full Transcript: Regenxbio Q2 2026 Earnings Call - Benzinga
Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Mizuho initiates Regenxbio stock coverage with outperform rating - Investing.com
ETFs Investing in REGENXBIO, Inc. Stocks - TradingView
Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0 - TradingView
H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data - Investing.com
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
Stifel reiterates Regenxbio stock rating on gene therapy data - Investing.com
Why is Regenxbio stock climbing today? - Investing.com India
Why is Regenxbio stock climbing today? - Investing.com
Regenxbio stock gains on positive gene therapy trial data - Investing.com
REGENXBIO reports three-year sura-vec Phase II results - grafa.com
Regenxbio stock gains on positive gene therapy trial data - Yahoo Finance
RGNX Looks 52.3% Undervalued on GF Value™ Despite Challenges - GuruFocus
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Singapore
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting - PR Newswire
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date - TradingView
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 188.83% Upside in Biotech Innovation - DirectorsTalk Interviews
REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance - AD HOC NEWS
Certain Warrants of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026. - marketscreener.com
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
REGENXBIO to Participate in Upcoming Investor Conferences - tradingview.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
This REGENXBIO Insider Increased Their Holding In The Last Year - Moomoo
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| Stephen J. Pakola | Officer |
Jul 01 '26 |
Proposed Sale |
11.98 |
43,206 |
517,608 |
0 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
| STEPHEN PAKOLA | Officer |
May 11 '26 |
Proposed Sale |
10.55 |
34,917 |
368,374 |
0 |
| PAKOLA STEVE | Chief Medical Officer |
May 11 '26 |
Sale |
11.02 |
15,309 |
168,705 |
232,617 |
| STEPHEN J PAKOLA | Officer |
Mar 10 '26 |
Proposed Sale |
10.38 |
5,124 |
53,187 |
0 |
4.22%
자본화:
|
볼륨(24시간):